[go: up one dir, main page]

DE3850019D1 - Rekombinantes Avipoxvirus. - Google Patents

Rekombinantes Avipoxvirus.

Info

Publication number
DE3850019D1
DE3850019D1 DE3850019T DE3850019T DE3850019D1 DE 3850019 D1 DE3850019 D1 DE 3850019D1 DE 3850019 T DE3850019 T DE 3850019T DE 3850019 T DE3850019 T DE 3850019T DE 3850019 D1 DE3850019 D1 DE 3850019D1
Authority
DE
Germany
Prior art keywords
avipox virus
recombinant avipox
recombinant
virus
avipox
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3850019T
Other languages
English (en)
Other versions
DE3850019T2 (de
Inventor
Noboru Yanagida
Sakiko Saeki
Ryohei Ogawa
Kouichi Kamogawa
Yoshiyuki Hayashi
Kazunari Sawaguchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zeon Corp
Original Assignee
Shionogi and Co Ltd
Nippon Zeon Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd, Nippon Zeon Co Ltd filed Critical Shionogi and Co Ltd
Publication of DE3850019D1 publication Critical patent/DE3850019D1/de
Application granted granted Critical
Publication of DE3850019T2 publication Critical patent/DE3850019T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE3850019T 1987-09-16 1988-09-15 Rekombinantes Avipoxvirus. Expired - Lifetime DE3850019T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP23165387 1987-09-16

Publications (2)

Publication Number Publication Date
DE3850019D1 true DE3850019D1 (de) 1994-07-14
DE3850019T2 DE3850019T2 (de) 1994-12-01

Family

ID=16926866

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3850019T Expired - Lifetime DE3850019T2 (de) 1987-09-16 1988-09-15 Rekombinantes Avipoxvirus.

Country Status (5)

Country Link
EP (1) EP0308220B1 (de)
KR (1) KR970000530B1 (de)
AU (1) AU611711B2 (de)
CA (1) CA1340203C (de)
DE (1) DE3850019T2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE115187T1 (de) * 1988-02-12 1994-12-15 Commw Scient Ind Res Org Poxvirus-vektoren.
DE3813093A1 (de) * 1988-04-19 1989-11-09 Immuno Ag Rekombinantes plasmid, verfahren zum herstellen eines rekombinanten avipoxvirus, rekombinantes avipoxvirus und dessen verwendung
US5631154A (en) * 1988-06-10 1997-05-20 Therion Biologics, Incorporated Self assembled, defective, non-self-propagating lentivirus particles
ES2061996T3 (es) * 1988-06-24 1994-12-16 British Tech Group Regiones no esenciales de avipoxvirus.
US5093258A (en) * 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector
KR940001265B1 (ko) * 1988-12-29 1994-02-18 닛뽕 제온 가부시끼가이샤 프로모터, 그를 함유하는 플라스미드 및 재조합 아비폭스비루스
JP2781605B2 (ja) * 1989-06-22 1998-07-30 日本ゼオン株式会社 組み換えアビポックスウイルス
WO1992000372A1 (en) * 1990-07-02 1992-01-09 Smithkline Beecham Corporation Recombinant pigeon pox virus vaccine
DE69133333T2 (de) * 1991-08-26 2004-07-29 Baxter Healthcare S.A. Ein intaktes FPV-tk-Gen enthaltender rekombinanter Virus der Vogelpocken
US5925358A (en) * 1993-02-26 1999-07-20 Syntro Corporation Recombinant fowlpox viruses and uses thereof
AU696247B2 (en) * 1993-02-26 1998-09-03 Syntro Corporation Recombinant fowlpox viruses and uses thereof
US6136318A (en) * 1993-02-26 2000-10-24 Cochran; Mark D. Recombinant fowlpox viruses and uses thereof
CA2158024C (en) * 1993-03-31 2000-09-12 Shuji Saitoh A mycoplasma gallisepticum antigen, dna encoding the antigen, recombinant vector bearing the dna and recombinant virus utilizing the recombinant vector as well as use thereof
JP4475683B2 (ja) 1996-07-25 2010-06-09 アメリカ合衆国 腫瘍関連抗原に対する免疫のための組換えポックス・ウイルス
ATE293690T1 (de) 1998-11-18 2005-05-15 Oxford Biomedica Ltd Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie
EP1601333B1 (de) 2003-02-20 2013-01-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Neue einführungsstellen in pocken-vektoren
CA2606287A1 (en) 2005-05-13 2006-11-16 Oxford Biomedica (Uk) Limited Peptide
EP2005184A2 (de) 2006-03-14 2008-12-24 Oregon Health and Science University Verfahren zum nachweis einer infektion mit mycobacterium tuberculosis
EP2444410A3 (de) 2007-02-28 2012-08-08 The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services Brachyurie-Polypeptide und Verwendungsverfahren
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
WO2010099472A2 (en) 2009-02-27 2010-09-02 The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services Spanx-b polypeptides and their use
EP2502076B1 (de) 2009-11-20 2018-04-18 Oregon Health and Science University Verfahren zum erkennen einer infektion mit dem mycobakterium tuberculosis
WO2012151272A2 (en) 2011-05-02 2012-11-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
EP2788021B1 (de) 2011-12-09 2017-01-18 Bavarian Nordic A/S Pockenvirus-vektor zur expression von bakteriellen antigen, welche mit tetanus toxin fragment c verbunden sind
WO2014043535A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer
PL3271729T3 (pl) 2015-03-18 2021-05-04 Janssen Vaccines & Prevention B.V. Oznaczenia systemów ekspresji rekombinowanej
WO2023077147A2 (en) 2021-11-01 2023-05-04 Pellis Therapeutics, Inc. T-cell vaccines for patients with reduced humoral immunity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0190254A4 (de) * 1984-07-05 1987-03-09 Genex Corp Kloniertes gen, verfahren zu dessen herstellung und seine verwendung.
EP0218625B1 (de) * 1985-03-29 1995-04-05 Btg International Limited Spike-protein des virus der infektiösen bronchitis
AU602875B2 (en) * 1985-12-18 1990-11-01 British Technology Group Limited Newcastle disease virus gene clones
EP0252060A1 (de) * 1986-06-30 1988-01-07 Smithkline Beckman - Animal Health Products DNA-Sequenz, rekombinante DNA-Moleküle und Verfahren zur Herstellung des von Newcastle-Krankheitsvirus-Fusionproteins oder der gleichwertigen Polypeptide, erhaltene Produkte und Präparate, die sie enthalten
WO1988002022A1 (en) * 1986-09-22 1988-03-24 Commonwealth Scientific And Industrial Research Or Recombinant poxviruses
AU605567B2 (en) * 1987-03-11 1991-01-17 Nippon Zeon Co., Ltd. Recombinant avipoxvirus
CA1341245C (en) * 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva

Also Published As

Publication number Publication date
KR970000530B1 (ko) 1997-01-13
AU611711B2 (en) 1991-06-20
EP0308220B1 (de) 1994-06-08
CA1340203C (en) 1998-12-15
EP0308220A1 (de) 1989-03-22
AU2222888A (en) 1989-03-16
DE3850019T2 (de) 1994-12-01
KR890005269A (ko) 1989-05-13

Similar Documents

Publication Publication Date Title
DE3853088D1 (de) Rekombinantes Avipoxvirus.
DE3850019D1 (de) Rekombinantes Avipoxvirus.
FR2621487B1 (fr) Virus avipox recombinant
ATE120489T1 (de) Rekombinante coccidiosis-vakzine.
DK603888D0 (da) Rekombinant virus
FI874819L (fi) Human rekombinant endotelcell vaextfaktor.
ATA902590A (de) Rekombinantes pockenvirus
FI871362L (fi) Virusvaccin.
DE4090351T1 (de) Rekombinantes Pockenvirus-Wirtsselektionssystem
DE3786767D1 (de) Neues polypeptid.
DE3785404D1 (de) Impfstoffe.
ATA257190A (de) Virales polypeptid
FI864016A0 (fi) Med rekombinant-dna-teknik erhaollen kolonistimulerande faktor-1.
DE69230627D1 (de) Rekombinantes Avipoxvirus
DE3683186D1 (de) Rekombinantes humaninterleukin-1.
NO881384D0 (no) Peptider.
NO885108D0 (no) Peptider.
NO873389L (no) Homogent rekombinant immun-interferon-fragment.
FI895456A0 (fi) Rekombinant interleukin 2-hybridproteiner.
FI864626L (fi) Rekombinantricintoxin.
DE3782960D1 (de) Impfstoffe.
FI875510A0 (fi) Virusdoedande komposition.
FI871885L (fi) Kombinationsvirus.
NO872386D0 (no) Peptider.
DE3890874T1 (de) Rekombinante avipoxviren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NIPPON ZEON CO., LTD., TOKIO/TOKYO, JP